Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemolysis01.06.04.0020.000049%
Haemolytic anaemia01.06.03.002--Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.006--Not Available
Hallucination19.10.02.002--
Head discomfort17.02.05.0270.000049%Not Available
Headache17.14.01.001--
Heart rate abnormal13.14.04.0060.000097%Not Available
Heart rate decreased13.14.04.0010.000097%Not Available
Heart rate increased13.14.04.002--Not Available
Hemiparesis17.01.04.001--
Henoch-Schonlein purpura24.07.06.003; 23.06.01.002; 10.02.02.004; 01.01.04.0010.000049%Not Available
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic fibrosis24.08.06.002; 09.01.04.0020.000049%Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000073%Not Available
Hepatitis09.01.07.004--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Herpes simplex23.09.03.001; 11.05.02.0010.000049%Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hip fracture15.08.03.001; 12.04.01.0010.000170%
Hypercalcaemia14.04.01.003; 05.04.01.0020.000097%
Hyperglycaemia14.06.02.002; 05.06.02.0020.000243%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.0010.000315%
Hyperparathyroidism secondary20.01.01.006; 05.04.01.0040.000073%Not Available
Hypersensitivity10.01.03.0030.000752%
Hypersomnia19.02.05.001; 17.15.01.0010.000073%
Hypertension24.08.02.0010.002184%
Hypertensive crisis24.08.01.0010.000558%Not Available
Hyperthyroidism14.11.01.011; 05.02.02.0010.000049%
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 19 Pages